KDx Diagnostics Inc. is committed to bringing to market novel non-invasive diagnostic tests to improve the accuracy of early detection and monitoring of cancer. KDx is developing tests based on cellular specimens, or cytology specimens, from bodily fluids and washings that can be obtained non-invasively to improve patient care. KDx will use novel cutting-edge biomarkers to improve accuracy of cancer detection while leveraging existing detection platforms and infrastructures for efficient adoption of the KDx tests in clinical settings.
With a presence in the global market, KDx is providing cutting-edge solutions to developed and developing countries where the clinical unmet needs are the greatest.
Simple technology allows easy adoption to reduce technical hurdles in all economic conditions.
Aggressively pursuing regulatory approval by conducting clinical studies for full compliance, resulting in clinical acceptance of the KDx tests.